CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

Latest:

Breaking down access barriers to newer preventive therapies Best responders to CGRP mAbs need treatment persistence CGRP mAbs do not significantly change inflammatory mediator levels Only half of treatment responders achieve IHS targets for migraine prevention Daily rimegepant dosing may have advantages for migraine prevention Potential biomarkers identified for erenumab responders HOPE trial results reinforce importance of comprehensive migraine symptom assessment Atogepant modifies endocannabinoid system and microRNAs

Korea7slide

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Korea7slide

Trials

Meeting Reports

Resources